Erythropoetin (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 211 | Hypoplastic left heart syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00513240 (ClinicalTrials.gov) | September 2006 | 7/8/2007 | Erythropoetin Neuroprotection for Neonatal Cardiac Surgery | Erythropoetin Neuroprotection for Neonatal Cardiac Surgery | Congenital Heart Disease;Hypoplastic Left Heart Syndrome;Transposition of the Great Arteries;Aortic Arch Hypoplasia or Interruption | Drug: Erythropoetin;Drug: Normal saline | Baylor College of Medicine | The Dana Foundation;Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | N/A | 30 Days | All | 62 | Phase 1;Phase 2 | United States |